Join
Live feed
·
PRReleasevia Quantisnow
Fortress Biotech Inc. logo

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

ByQuantisnow·Wall Street's wire, on your screen.
FBIO· Fortress Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBIO (Fortress Biotech Inc.) and more on Quantisnow.